Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Florbetapir f-18
Drug ID BADD_D00907
Description Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. Marketed as the product Amyvid, florbetapir 18F is indicated for positron emission tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.
Indications and Usage Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB09149
KEGG ID D09617
MeSH ID C545186
PubChem ID 24822371
TTD Drug ID D09CGE
NDC Product Code Not Available
UNII 6W15Z5R0RU
Synonyms florbetapir | 2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-5-(4-methylaminostyryl)pyridine | 4-(2-(6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzamide | Amyvid | 18F-AV-45 | florbetapir F 18 | florbetapir F18
Chemical Information
Molecular Formula C20H25FN2O3
CAS Registry Number 956103-76-7
SMILES CNC1=CC=C(C=C1)C=CC2=CN=C(C=C2)OCCOCCOCCF
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anxiety19.06.02.002--
Asthenia08.01.01.001---
Back pain15.03.04.005--
Blood pressure increased13.14.03.005---
Claustrophobia19.06.03.005---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dysgeusia07.14.03.001; 17.02.07.003--
Fatigue08.01.01.002--
Feeling cold08.01.09.008---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Headache17.14.01.001--
Injection site reaction08.02.03.014; 12.07.03.015--
Insomnia17.15.03.002; 19.02.01.002--
Musculoskeletal pain15.03.04.007--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Pruritus23.03.12.001--
Urticaria10.01.06.001; 23.04.02.001--
Infusion site rash08.02.05.017; 12.07.05.017; 23.03.13.018---
The 1th Page    1    Total 1 Pages